AI model trained on living human skin for a month
Outer Biosciences develops AI models by keeping surgically discarded human skin alive for up to a month.
1Four years in stealth mode
Outer Biosciences, a Massachusetts-based biotech company, succeeded in keeping human skin alive outside the body for four years. Their system preserves surgically removed tissues for up to a month, developed by a 19-person team that raised $23 million in funding. Experiments conducted during this period without any public disclosure provided critical data for training the AI model.
2AI-powered cyclical learning
The company's system uses an AI model that predicts effects of untested chemicals on skin functions. Living tissue tests verify or revise the model's predictions. This closed-loop approach now generates a new compound candidate every six weeks, compared to finding just a few leads through literature review in 18 months previously.
3Focus on cosmetic industry
Outer Biosciences chooses to discover cosmetic ingredients rather than pharmaceutical drugs. This strategy only requires passing OECD safety tests instead of facing strict medical regulations. The EU's decade-long ban on animal testing created favorable conditions for developing alternative methods. The cosmetic industry uses standardized nomenclature for ingredients.
4Tissue sources and ethical standards
Human skin samples for experiments primarily come from discarded tissues after cosmetic surgeries. Tissues are sourced through biobanks and brokers under institutional review board oversight with documented donor consent. Rather than purchasing tissues, the company pays cost recovery fees and confirms all identifiers are removed before samples reach their labs.
5Technological differentiation
The company maintains living tissue samples far beyond conventional durability limits - up to one month. While standard methods only allow days of viability (sufficient for acute toxicity tests), their approach enables studying collagen remodeling, pigmentation changes, and barrier repair that take weeks to manifest. Month-old samples reportedly maintain day-one-like characteristics.
6Impact on European market
The European Commission's June 1 roadmap proposes phasing out animal testing in chemical safety assessments. With over 30 recommendations, this plan introduces significant regulations in a market where AI biology advances faster than validation systems. Europe's created demand is being met by American companies like Outer.
7Competitive landscape
Outer Biosciences isn't alone in this field. Vivodyne raised nearly $80 million for lab-grown human tissues, while organ-on-chip companies target the same preclinical market. Outer differentiates through physical data collection - emphasizing that biology data can't be scraped from the internet and processing occurs on their own machines rather than in the cloud.
8Industry milestone
Outer Biosciences' work represents a revolutionary approach for cosmetic and pharmaceutical industries. This animal testing alternative addresses ethical concerns while accelerating research processes. AI-powered biology research progresses at a pace that challenges regulatory bodies to keep up, marking a significant turning point for the field.
Original article: The Next Web — Yapay zeka canlı deri üzerinde eğitiliyor